
CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,



(I),

wherein

R^1 is Cl, CH_3, $-OCF_3$ or CF_3;

R^2 is halo, C_1-C_4alkyl or haloC_1-C_4alkyl;

R^3 is H, CN, C_1-C_4alkyl or haloC_1-C_4alkyl;

R^4 is $–(CH_2)_n$-OH, wherein n is 1, 2, 3 or 4;

R^5 is a mono or bicyclic heterocyclyl, which is unsubstituted or substituted with 1 to 2 substituents independently selected from C_1-C_4alkyl, haloC_1-C_4alkyl, hydroxyC_1-C_4alkyl, -OH, halo, oxo, and $-CO_2H$; or

R^5 is an aryl or heteroaryl, which is unsubstituted or substituted with 1 to 2 substituents independently selected from halo, haloC_1-C_4alkyl, C_1-C_4alkyl, and $-SO_2NH_2$; or

R^5 is C_3-C_6cycloalkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from C_1-C_4alkyl, halo, haloC_1-C_4alkyl, and –OH; or

R^5 is C_2-C_6alkyl substituted with 1 or more substituents independently selected from –OH, C_1-C_4alkoxy, halo, $-NH_2$, $-NH(C_1$-C_4alkyl), and $-N(C_1$-C_4alkyl$)_2$,

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^1 is $-OCF_3$ or CF_3;

R^2 is C_1-C_4alkyl or haloC_1-C_4alkyl;

R^3 is H, C_1-C_4alkyl or haloC_1-C_4alkyl;

R^4 is $–CH_2$-OH;

R^5 is a mono or bicyclic heterocyclyl, which is unsubstituted or substituted with 1 to 2 substituents independently selected from C_1-C_4alkyl, haloC_1-C_4alkyl, hydroxyC_1-C_4alkyl, -OH, halo, oxo, and $-CO_2H$; or

R^5 is an aryl or heteroaryl, which is unsubstituted or substituted with 1 to 2 substituents independently selected from halo, haloC_1-C_4alkyl, C_1-C_4alkyl, and $-SO_2NH_2$; or

R^5 is C_3-C_6cycloalkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from C_1-C_4alkyl, halo, haloC_1-C_4alkyl, and –OH; or

R^5 is C_2-C_6alkyl substituted with 1 or more substituents independently selected from –OH, C_1-C_4alkoxy, halo, -NH_2, -NH(C_1-C_4alkyl), and -N(C_1-C_4alkyl)$_2$.

3. The compound according to claims 1 or 2, or a pharmaceutically acceptable salt thereof, wherein

R^1 is -OCF_3 or CF_3;

R^2 is C_1-C_4alkyl;

R^3 is H;

R^4 is –CH_2-OH;

R^5 is a mono or bicyclic heterocyclyl, which is unsubstituted or substituted with 1 to 2 substituents independently selected from C_1-C_4alkyl, haloC_1-C_4alkyl, hydroxyC_1-C_4alkyl, -OH, halo, oxo, and -CO_2H; or


R^5 is an aryl or heteroaryl, which is unsubstituted or substituted with 1 to 2 substituents independently selected from halo, haloC_1-C_4alkyl, C_1-C_4alkyl, and -SO_2NH_2; or

R^5 is C_3-C_6cycloalkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from C_1-C_4alkyl, halo, haloC_1-C_4alkyl, and –OH; or

R^5 is C_2-C_6alkyl substituted with 1 or more substituents independently selected from –OH, C_1-C_4alkoxy, halo, -NH_2, -NH(C_1-C_4alkyl), and -N(C_1-C_4alkyl)$_2$.


4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^5 is a mono or bicyclic heterocyclyl, which is unsubstituted or substituted with 1 to 2 substituents independently selected from C_1-C_4alkyl, haloC_1-C_4alkyl, hydroxyC_1-C_4alkyl, -OH, halo, oxo and -CO_2H.

5. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from the following:




wherein R^{5a} is independently selected from C_1-C_4alkyl, hydroxyC_1-C_4alkyl and H; and R^{5b} is independently selected from -OH, hydroxyC_1-C_4alkyl, H, halo, oxo, haloC_1-C_4alkyl and -CO_2H; X is O or CH_2; and m is 0 or 1, and wherein "*" indicates the carbon attached to the pyridazine-amine.

6. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from the following:




wherein R^{5a} is independently selected from C_1-C_4alkyl, hydroxyC_1-C_4alkyl, and H; and R^{5b} is independently selected from -OH, C_1-C_4alkyl, hydroxyC_1-C_4alkyl, H, halo, oxo, haloC_1-C_4alkyl, and -CO_2H; X is O or CH_2; and m is 0 or 1, and wherein "*" indicates the carbon atom attached to the pyridazine-amine.

7. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from the following:



wherein R^{5a} is independently selected from C_1-C_4alkyl, hydroxyC_1-C_4alkyl, and H; and R^{5b} is independently selected from -OH, C_1-C_4alkyl, hydroxyC_1-C_4alkyl, H, halo, oxo, haloC_1-C_4alkyl, and -CO_2H; and m is 0 or 1, and wherein "*" indicates the carbon atom attached to the pyridazine-amine.

8. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^5 is



,

wherein R^{5a} is independently selected from C_1-C_4alkyl, hydroxyC_1-C_4alkyl and H, and wherein "*" indicates the carbon atom attached to the pyridazine-amine.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R^{5a} is methyl or H, in particular R^{5a} is methyl.

10. The compound according to claim 1, wherein the compound is
(*R*)-2-(5-(hydroxymethyl)-6-((1-methylpiperidin-3-yl)amino)pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol (example 1),
or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

12. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents.

13. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 11, or the combination according to claim 12, for use as a medicament.

14. Use of a compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament in the treatment of a disease or disorder in which NLRP3 signaling contributes to the pathology, and/or symptoms, and/or progression, of said disease or disorder.

15. The use according to claim 14, wherein the disease or disorder is selected from inflammasome-related diseases / disorders, immune diseases, inflammatory diseases, auto-immune diseases, or auto-inflammatory diseases, for example, autoinflammatory fever syndromes, cryopyrin-associated periodic syndrome, liver related diseases / disorders, chronic liver disease, viral hepatitis, non-alcoholic steatohepatitis, alcoholic steatohepatitis, and alcoholic liver disease, inflammatory arthritis related disorders, gout, calcium pyrophosphate dihydrate crystal deposition disease, osteoarthritis, rheumatoid arthritis, arthropathy, kidney related diseases, hyperoxaluria, lupus nephritis, Type I / Type II diabetes and related complications, nephropathy, retinopathy, hypertensive nephropathy, hemodialysis related inflammation, neuroinflammation-related diseases, multiple sclerosis, brain infection, acute injury, neurodegenerative diseases, Alzheimer's disease, cardiovascular / metabolic diseases / disorders, cardiovascular risk reduction, hypertension, atherosclerosis, type I and type II diabetes and related complications, peripheral artery disease, acute heart failure, inflammatory skin diseases, hidradenitis suppurativa, acne, wound healing and scar formation, asthma, sarcoidosis, age-related macular degeneration, and cancer related diseases / disorders, colon cancer, lung cancer, myeloproliferative neoplasms, leukemias, myelodysplastic syndromes, myelofibrosis, chronic obstructive pulmonary disorder, chronic myelomonocytic leukaemia, post-Myocardial Infarction Heart Failure.